How late they left this raise was nothing short of reckless.
Classic Aussie bio tech. Great products, terrible management. But similarly, selling below the raise price because they came up a bit short a bit silly. Buying dribs and drabs here ahead of hopefully a quarterly that shows some clear momentum TOWARDS cash flow positivity, clearly still quite a way off.
Bio-tech executives have had 15 years of easing monetary conditions. They have to start earning their keep now, and many don't know how.
Add to My Watchlist
What is My Watchlist?
